PL1748767T3 - 1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy - Google Patents

1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy

Info

Publication number
PL1748767T3
PL1748767T3 PL05762186T PL05762186T PL1748767T3 PL 1748767 T3 PL1748767 T3 PL 1748767T3 PL 05762186 T PL05762186 T PL 05762186T PL 05762186 T PL05762186 T PL 05762186T PL 1748767 T3 PL1748767 T3 PL 1748767T3
Authority
PL
Poland
Prior art keywords
binuclear
present
diarylalkanes
diarylalkanols
preventing
Prior art date
Application number
PL05762186T
Other languages
English (en)
Inventor
Qi Jia
Ji-Fu Zhao
Original Assignee
Unigen Inc
Qi Jia
Zhao Ji Fu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigen Inc, Qi Jia, Zhao Ji Fu filed Critical Unigen Inc
Publication of PL1748767T3 publication Critical patent/PL1748767T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/32—Preparation of ethers by isomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/12—Eight-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
PL05762186T 2004-05-28 2005-05-27 1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy PL1748767T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57559904P 2004-05-28 2004-05-28
PCT/US2005/018884 WO2005117849A1 (en) 2004-05-28 2005-05-27 Diarylalkanes as potent inhibitors of binuclear enzymes
EP05762186A EP1748767B1 (en) 2004-05-28 2005-05-27 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane as a potent tyrosinase inhibitor

Publications (1)

Publication Number Publication Date
PL1748767T3 true PL1748767T3 (pl) 2012-08-31

Family

ID=35462712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05762186T PL1748767T3 (pl) 2004-05-28 2005-05-27 1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy

Country Status (14)

Country Link
US (8) US20050267047A1 (pl)
EP (1) EP1748767B1 (pl)
JP (1) JP5128277B2 (pl)
KR (2) KR20120117948A (pl)
CN (4) CN109134205B (pl)
AT (1) ATE538778T1 (pl)
AU (1) AU2005249493B2 (pl)
CA (1) CA2567801C (pl)
ES (1) ES2384506T3 (pl)
MX (1) MXPA06013705A (pl)
PL (1) PL1748767T3 (pl)
RU (2) RU2006140961A (pl)
WO (1) WO2005117849A1 (pl)
ZA (1) ZA200609927B (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023200786A1 (en) 2022-04-12 2023-10-19 Unigen, Inc. Diarylalkane compounds and compositions for use with skin aging and methods of production thereof

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5128277B2 (ja) 2004-05-28 2013-01-23 ユニジェン・インコーポレーテッド 二核酵素の強力な阻害剤としてのジアリールアルカン類
DE102005044156A1 (de) * 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate
FR2910808B1 (fr) * 2006-12-29 2009-04-10 Lvmh Rech Utilisation en cosmetique de la l-2-thiohistidine ou d'un de ses derives comme agent depigmentant.
KR100909768B1 (ko) * 2007-10-31 2009-07-29 주식회사 코리아나화장품 감태나무 추출물을 유효성분으로 함유하는 피부노화 방지용화장료 조성물
KR101661608B1 (ko) * 2008-07-21 2016-09-30 유니젠, 인크. 일련의 피부-화이트닝(라이트닝) 화합물
MY160942A (en) * 2008-12-22 2017-03-31 Pola Chem Ind Inc Melanin production inhibitor
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
MX339842B (es) 2009-12-22 2016-06-14 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
CN103989589B (zh) * 2010-03-31 2018-08-21 株式会社爱茉莉太平洋 含有香豆雌酚或包含香豆雌酚的豆提取物的、用于皮肤护理的化妆品组合物
KR101831366B1 (ko) * 2010-06-18 2018-04-04 (주)아모레퍼시픽 닥나무 추출물 제조 방법
KR101830860B1 (ko) * 2010-07-13 2018-02-21 (주)아모레퍼시픽 닥나무 추출물을 함유하는 항노화용 화장료 조성물
KR101681683B1 (ko) * 2010-07-02 2016-12-01 (주)아모레퍼시픽 닥나무의 꽃과 열매 추출물을 함유하는 피부 미백용 피부 외용제 조성물
JP5944896B2 (ja) * 2010-07-02 2016-07-05 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ コウゾ抽出物を含有する組成物
KR101761771B1 (ko) * 2010-07-14 2017-07-26 (주)아모레퍼시픽 닥나무 또는 그 추출물의 발효방법, 그 발효 추출물 및 이를 포함하는 화장료 조성물
KR101769935B1 (ko) * 2010-07-14 2017-08-21 (주)아모레퍼시픽 닥나무 추출물을 제조하는 방법, 그에 의해 제조된 닥나무 추출물 및 이를 포함하는 화장료 조성물
WO2012033634A2 (en) 2010-09-09 2012-03-15 Mary Kay Inc. Topical skin care formulations comprising plant extracts
CN103561718B (zh) * 2010-12-30 2020-06-16 雅芳产品公司 皮肤中动力蛋白的调节
FR2970416B1 (fr) * 2011-01-18 2013-02-22 Fabre Pierre Dermo Cosmetique Nouveaux derives monoterpeniques de chalcone ou dihydrochalcone et leur utilisation comme depigmentants
WO2012129260A1 (en) 2011-03-24 2012-09-27 Unigen, Inc. Compounds and methods for preparation of diarylpropanes
DE102011114780A1 (de) * 2011-10-01 2013-04-04 Merck Patent Gmbh Verwendung von Propanol- und Propenolderivaten als Antioxidantien
FR2984730A1 (fr) 2011-12-22 2013-06-28 Diverchim Nouvelles compositions cosmetiques anti-age et depigmentantes
KR101424360B1 (ko) 2012-07-03 2014-08-01 영남대학교 산학협력단 하이드록시 챨콘 화합물을 유효성분으로 함유하는 항암용 조성물
JP6207336B2 (ja) * 2012-11-12 2017-10-04 日本ポリプロ株式会社 ジオール化合物及びオレフィン重合用触媒並びにオレフィン重合体の製造方法
MD4274C1 (ro) * 2013-05-27 2014-09-30 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Azotat de trans-bis(dimetilglioximato)bis(nicotinamid)cobalt(III)dihidrat, ce manifestă proprietăţi antioxidante la plante
WO2015122858A1 (en) 2014-02-15 2015-08-20 Erdal Can Alkoçlar A composition containing synthetic components formed for suppressing ribonucleotide reductase
FR3030510B1 (fr) 2014-12-22 2017-02-03 Oreal Composes 1-phenyl (3,4-disubstitues), 2-phenyl (3,4-disubstitues) ethane et leur utilisation
WO2016116059A1 (zh) * 2015-01-22 2016-07-28 高雄医学大学 用于治疗代谢症候群的组合物及其制备方法
MX385256B (es) 2015-04-15 2025-03-14 Natura Cosmeticos Sa Composicion para formulacion cosmetica humectante de larga duracion que comprende manteca de ucuuba con altas concentraciones de acido miristico asi como el uso de la formulacion para la preparacion de un producto cosmetico altamente humectante y kit.
CN105726410B (zh) * 2016-03-29 2019-01-04 中国科学院成都生物研究所湖州生物资源利用与开发创新中心 山菅兰的活性提取物及其制备方法和应用
CN109310649B (zh) * 2016-04-28 2021-06-29 西姆莱斯有限公司 影响炎性状态的二氢查耳酮衍生物
CN108530273A (zh) * 2018-04-26 2018-09-14 武汉桀升生物科技有限公司 一种2,4-二甲氧基-甲苯基-4-丙基间苯二酚的合成方法
CN110305014B (zh) * 2019-03-15 2022-02-15 沈阳药科大学 环新木脂烷型木脂素对映异构体及其制备和应用
CN116196299B (zh) * 2022-07-28 2023-10-03 昆明医科大学 1,3-二芳基丙烷类衍生物在制备酪氨酸酶抑制剂中的应用
CN119490528A (zh) * 2025-01-17 2025-02-21 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种HSP90α选择性抑制剂及其合成方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA238730A (en) 1924-03-18 R. Curme Henry Process of oxidising dibenzyl
US1596613A (en) * 1925-12-15 1926-08-17 Lehn & Fink Inc 2, 4-dihydroxydiphenylethane and process of making it
US3133967A (en) * 1960-02-04 1964-05-19 Boehringer Sohn Ingelheim 1-(3, 4-dialkoxy-phenol)-1-dialkylamino-3-and-4-piienyl butanes
JPS496311B1 (pl) 1970-01-09 1974-02-13
DE2644591A1 (de) 1976-10-02 1978-04-06 Bayer Ag Verfahren zur herstellung von arylsulfoniumsalzen
PH18415A (en) 1978-03-15 1985-06-24 Wellcome Found Flavan derivatives,pharmaceutical compositions and use thereof
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
EP0028305B1 (en) 1979-09-13 1984-02-01 The Wellcome Foundation Limited Diaryl compounds and pharmaceutical formulations containing them
JPS5758610A (en) 1980-09-26 1982-04-08 Lion Corp Composition for oral cavity
US4678664A (en) * 1982-09-30 1987-07-07 Basf Corporation Mineral oil gels
EP0122523A3 (en) 1983-04-18 1987-05-27 Andrews Paper and Chemical Co., Inc. Diazotype compositions and materials
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
KR890700023A (ko) * 1986-11-19 1989-03-02 케맥스 파마슈우티칼스 인코포레이티드 리폭시게나제 저해제
FR2609711B1 (fr) 1987-01-21 1989-06-16 Rhone Poulenc Chimie Procede de preparation d'hydroxybiphenyles
US4954659A (en) * 1987-10-21 1990-09-04 Chemex Pharmaceuticals, Inc. 1,4-bis (dihydroxyphenyl) butane and analogs
CA1327869C (en) * 1989-02-17 1994-03-15 Yvan Guindon Ribonucleotide reductase inhibitors
JPH03242650A (ja) 1990-02-20 1991-10-29 Fuji Photo Film Co Ltd ポジ型フオトレジスト組成物
JPH05213729A (ja) * 1992-01-31 1993-08-24 Kao Corp メラニン抑制剤
AU4385293A (en) * 1992-05-21 1993-12-13 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
IT1256354B (it) * 1992-08-31 1995-12-01 Francesca Pelizzoni Derivati della combretastatina ad attivita' anti-tumorale e procedimento per la loro preparazione
GB9322007D0 (en) * 1993-10-26 1993-12-15 Unilever Plc Cosmetic composition
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US7056935B2 (en) * 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
JPH08337510A (ja) * 1995-06-15 1996-12-24 Advanced Sukin Res Kenkyusho:Kk メラニン生成抑制剤
JP3072267B2 (ja) * 1995-11-24 2000-07-31 鐘紡株式会社 ハイドロカルコン誘導体、該誘導体を含む化粧料及びこれらの製造方法
ES2154844T3 (es) * 1995-11-24 2001-04-16 Mitsui Chemicals Inc Derivados de hidrocalcona, composiciones cosmeticas que contienen dichos derivados y procedimientos para producir los mismos.
RU2156771C2 (ru) 1996-05-30 2000-09-27 Институт нефтехимии и катализа с опытным заводом АН РБ Способ совместного получения 1-(диалкиламино)-2-фенилалюмациклопропана и 1-(диалкиламино)-2,4-дифенилалюмациклопентана
DE19651681A1 (de) * 1996-12-12 1998-06-18 Basf Ag Stabile, wäßrige Dispersionen und stabile, wasserdispergierbare Trockenpulver von Xanthopyllen, deren Herstellung und Verwendung
PT1015446E (pt) * 1997-02-07 2003-08-29 Aventis Pharma Inc Derivados de (4-piperidinil)-1h-2-benzopirano uteis como agentes antipsicoticos
KR100270410B1 (ko) * 1997-03-06 2000-11-01 성재갑 타이로시네이즈 활성 저해능을 갖는 신규 1,3-디페닐프로판 유도체 및 그의 제조방법
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
US6376546B1 (en) 1997-10-14 2002-04-23 Asahi Kasei Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
JPH11255638A (ja) 1998-03-13 1999-09-21 Kansai Kouso Kk チロシナーゼ活性阻害剤及び化粧料
WO2000015214A1 (en) * 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
US6296857B1 (en) * 1998-09-23 2001-10-02 Beiersdorf Aktiengesellschaft Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by UV radiation
JP2000095721A (ja) * 1998-09-28 2000-04-04 Mitsui Chemicals Inc 新規ハイドロカルコン誘導体、該誘導体を含む化粧料およびこれらの製造方法
WO2000073269A2 (en) * 1999-06-02 2000-12-07 Regents Of The University Of Minnesota Nicotine receptor ligands
FR2796278B1 (fr) 1999-07-16 2002-05-03 Oreal Utilisation d'au moins un hydroxystilbene comme agent anti-glycation
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6221604B1 (en) 2000-02-07 2001-04-24 Pe Corporation Electron-deficient nitrogen heterocycle-substituted fluorescein dyes
AU2001243334A1 (en) 2000-02-29 2001-09-12 Integriderm, Inc. Inhibitors of melanocyte tyrosinase as topical skin lighteners
JP2001335472A (ja) 2000-05-24 2001-12-04 Kansai Koso Kk チロシナーゼ活性阻害剤及び化粧料
MXPA03000043A (es) * 2000-06-30 2003-10-15 Procter & Gamble Promocion de la salud en todo el cuerpo.
JP3504594B2 (ja) * 2000-07-28 2004-03-08 株式会社ノエビア 皮膚外用剤
EP1191030B1 (en) 2000-09-21 2005-05-04 Solvias AG Phosphinite-oxazolines and metal complexes
BR0114059A (pt) 2000-09-21 2003-07-01 Pfizer Prod Inc Derivados de resorcinol
DE10051034A1 (de) * 2000-10-14 2002-04-18 Henkel Kgaa Oxidationsmittel enthaltend 2-Chlor-4-aminophenol
AU2002227138A1 (en) 2000-10-24 2002-05-06 Molecular Electronics Corporation Three-terminal field-controlled molecular devices
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
JP2002193990A (ja) * 2000-12-25 2002-07-10 Mitsui Chemicals Inc ハイドロカルコン配糖体および該配糖体を有効成分として配合した化粧料
MXPA03008699A (es) 2001-05-25 2003-12-12 P & G Clairol Inc Derivados de 1,3-dihidroxibenceno y agentes colorantes que contienen estos compuestos.
JP4425628B2 (ja) * 2001-07-23 2010-03-03 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 細胞保護化合物、薬学的処方物および美容用処方物、ならびに方法
GB0126889D0 (en) * 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
DE10161253A1 (de) * 2001-12-13 2003-06-26 Dragoco Gerberding Co Ag Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
US6600004B1 (en) 2002-04-10 2003-07-29 General Electric Company Method of preparing polyestercarbonates
WO2003086414A1 (en) * 2002-04-10 2003-10-23 Arizona Board Of Regents Structural modification of resveratrol: sodium resverastatin phosphate
CN1462739A (zh) 2002-05-30 2003-12-24 浙江工业大学 2,2'－二氨基联苄二磷酸盐低压液相催化加氢制备方法
CN1176964C (zh) 2002-07-12 2004-11-24 丛树枫 弹性高强度聚氨酯预聚物的制备方法及其应用
SI1611112T1 (sl) 2003-02-11 2012-12-31 Vernalis (R&D) Limited Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov
CN1238361C (zh) 2003-02-21 2006-01-25 南开大学 螺环双膦配体
DE10324566A1 (de) 2003-05-30 2004-12-16 Symrise Gmbh & Co. Kg Verwendung von Diphenylmethan-Derivaten als Tyrosinase-Inhibitoren
JP4569211B2 (ja) 2003-07-31 2010-10-27 住友ベークライト株式会社 フェノール化合物、ポジ型感光性樹脂組成物、半導体装置及び表示素子、並びに半導体装置及び表示素子の製造方法
JP2005097144A (ja) 2003-09-24 2005-04-14 Mitsubishi Chemicals Corp ２核フェノール類の製造方法
JP5128277B2 (ja) 2004-05-28 2013-01-23 ユニジェン・インコーポレーテッド 二核酵素の強力な阻害剤としてのジアリールアルカン類
US7334392B2 (en) 2004-10-29 2008-02-26 General Electric Company Counter-rotating gas turbine engine and method of assembling same
US20070224301A1 (en) 2006-03-21 2007-09-27 Ribnicky David M Compounds from an extract of Artemisia and methods for treating disorders
US7781410B2 (en) 2006-08-04 2010-08-24 Johnson & Johnson Consumer Companies, Inc. Compositions containing chalcones and use thereof
KR101661608B1 (ko) 2008-07-21 2016-09-30 유니젠, 인크. 일련의 피부-화이트닝(라이트닝) 화합물
WO2012129260A1 (en) 2011-03-24 2012-09-27 Unigen, Inc. Compounds and methods for preparation of diarylpropanes
WO2018037388A1 (en) 2016-08-26 2018-03-01 1Qb Information Technologies Inc. Method and system for performing real-time analytics on a plurality of data streams

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023200786A1 (en) 2022-04-12 2023-10-19 Unigen, Inc. Diarylalkane compounds and compositions for use with skin aging and methods of production thereof

Also Published As

Publication number Publication date
CN103356514A (zh) 2013-10-23
CA2567801A1 (en) 2005-12-15
US20210085580A1 (en) 2021-03-25
US9126913B2 (en) 2015-09-08
KR20120117948A (ko) 2012-10-24
JP2008501030A (ja) 2008-01-17
CN102210663B (zh) 2013-07-31
KR101236527B1 (ko) 2013-02-22
US20130224135A1 (en) 2013-08-29
US10857082B2 (en) 2020-12-08
US20200170907A1 (en) 2020-06-04
RU2006140961A (ru) 2008-07-10
CN109134205B (zh) 2022-07-19
ES2384506T3 (es) 2012-07-06
EP1748767A1 (en) 2007-02-07
US20160193126A1 (en) 2016-07-07
US7767661B2 (en) 2010-08-03
RU2466981C1 (ru) 2012-11-20
US8592488B2 (en) 2013-11-26
US20140371491A1 (en) 2014-12-18
US20050267047A1 (en) 2005-12-01
MXPA06013705A (es) 2007-02-13
US8729136B2 (en) 2014-05-20
ATE538778T1 (de) 2012-01-15
HK1095536A1 (en) 2007-06-29
CN1993114A (zh) 2007-07-04
WO2005117849A1 (en) 2005-12-15
ZA200609927B (en) 2008-07-30
US20100267839A1 (en) 2010-10-21
AU2005249493A1 (en) 2005-12-15
AU2005249493B2 (en) 2011-09-08
BRPI0510415A (pt) 2007-10-23
CN102210663A (zh) 2011-10-12
KR20070034538A (ko) 2007-03-28
JP5128277B2 (ja) 2013-01-23
CA2567801C (en) 2013-12-03
US11857657B2 (en) 2024-01-02
EP1748767A4 (en) 2008-12-24
CN109134205A (zh) 2019-01-04
US10548825B2 (en) 2020-02-04
CN1993114B (zh) 2011-05-11
US20080132581A1 (en) 2008-06-05
EP1748767B1 (en) 2011-12-28

Similar Documents

Publication Publication Date Title
PL1748767T3 (pl) 1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy
WO2003024448A3 (en) Inhibitors of histone deacetylase
WO2001070675A3 (en) Inhibitors of histone deacetylase
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
BR0317183A (pt) Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
KR950702180A (ko) 류코트리엔 생합성 억제제로서의 치환된 아릴알키닐-및 헤테로아릴알키닐-N-하이드록시우레아(substituted arylalkynyl-and heteroarylalkyny-N-hydroxyurea inhibi tors of leukotriene biosynthesis)본 내용은 요부공개 건이므로 전문 내용을 수록하지 않았음
DE69816280D1 (de) Inhibitoren des impdh-enzyms
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE602004026407D1 (en) Histondeacetylase-hemmer
NO20061194L (no) Mitotiske kinesininbibitorer
BR0208373A (pt) Inibidores da tirosina cinase
BG104780A (en) Inhibitors of phospholipase enzymes
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
EP1748046A3 (en) Inhibitors of histone deacetylase
WO2010001169A3 (en) Chemical compounds 251
WO2008063382A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
WO2008042282A3 (en) Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
WO2008014426A3 (en) Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
WO2002005642A3 (en) Synergistic biocidal compositions
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
EP1307096A4 (en) COMPOSITIONS AND METHODS FOR PRESERVING PLANTS
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells
EP1161943A3 (en) Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds